Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 0.47 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12574308 | 0.85 | TSPO (0.50) | TSPOGPBAR1PAX8TLR9CA1 | |
| SCHEMBL8779753 | 0.83 | TSPO (0.53) | TSPOGPBAR1PAX8TLR9CA1 | |
| SCHEMBL30743858 | 0.83 | PAX8 (0.52) | PAX8TLR9CA1CA2CA12 | |
| SCHEMBL2536563 | 0.83 | TSPO (0.67) | TSPOGPBAR1PAX8TLR9CA1 | |
| SCHEMBL22879480 | 0.83 | PAX8 (0.52) | PAX8TLR9CA1CA2CA12 | |
| SCHEMBL10481539 | 0.81 | TSPO (0.47) | TSPOGPBAR1PAX8TLR9CA1 | |
| SCHEMBL7816426 | 0.81 | TSPO (0.47) | TSPOGPBAR1PAX8TLR9CA1 | |
| SCHEMBL10939691 | 0.81 | TSPO (0.47) | TSPOGPBAR1PAX8TLR9CA1 | |
| SCHEMBL11751605 | 0.81 | CA1 (0.43) | TSPOGPBAR1PAX8TLR9CA1 | |
| SCHEMBL24393532 | 0.79 | CA1 (0.47) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018109496-A2 | UNNATURAL AMINO ACIDS | THE UNIVERSITY OF BRISTOL (GB) | 2018-06-21 | — | — | WO | disclosed |
| EP-2655323-B1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LTD (IE) | 2017-12-20 | — | — | EP | disclosed |
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2017-08-03 | — | — | US | disclosed |
| US-9708286-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2017-07-18 | — | — | US | disclosed |
| CN-104529827-B | Ingenol-3-acylate III and ingenol-3-carbamate | 利奥实验室有限公司 | 2016-08-24 | — | — | CN | disclosed |
| US-20150291551-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2015-10-15 | — | — | US | disclosed |
| US-9102687-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2015-08-11 | — | — | US | disclosed |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2014-10-09 | — | — | US | disclosed |
| EP-2655323-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012083953-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
| US-4053298-A | HERBICIDAL COMPOSITIONS CONTAINING 1-THIADIAZOLYL-6-CARBAMOYLOXYTETRAHYDROPYRIMIDINONES AND METHODS THEREFOR | VELSICOL CHEMICAL CORPORATION (US) | 1977-10-11 | — | — | US | disclosed |
| US-4023957-A | Herbicidal 1-thiadiazolyl-5-carbamoyloxyimidazolidinones | VELSICOL CHEMICAL CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-3951976-A | 1-Thiadiazoly-6-carbamoyloxytetrahydropyrimidinones | VELSICOL CHEMICAL CORPORATION (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | TSPO 2751/4885GPBAR1 339/4885PAX8 172/4885 |
| US-20150291551-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | TSPO 2751/4885GPBAR1 339/4885PAX8 172/4885 |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | TSPO 2751/4885GPBAR1 339/4885PAX8 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.